For the former therapies, it is worthy to note that recent proofs suggest that the net benefit of FXa inhibitors in cancer may be at least in part independent of their antithrombotic effects, for instance, by enhancing the efficacy of immune checkpoint inhibitors [58], which in turn may stimulate an increased TF expression [59]. The gene discussed is F10; the disease is cancer.